Amylyx Takes Heat for $158,000 Annual Price of New ALS Drug

October 4, 2022

Amylyx Pharmaceuticals’ new amyotrophic lateral sclerosis (ALS) drug was approved by the US Food and Drug Administration last week and is already taking flak. The company has set the annual price of the drug to $158,000, a number decried by many as exorbitant. According to ICER, the drug should be priced no higher than $30,000 a year until more evidence comes in regarding the drug’s efficacy.

According to Nicole Raleigh, “‘Clearer’ data isn’t expected until 2024, with results from a late-stage phase 3 PHOENIX trial of around 600 patients due at that time. Most patients are only now being enrolled in Europe, according to co-chief executive officers of Amylyx Justin Klee and Joshua Cohen, who say they arrived at the price following discussions with patients, as well as insurers and other stakeholders, but also mindful of future funding of research.”

To read more, click here.

(Source: PharmaPhorum, October 3rd, 2022)

Share This Story!